Compare IDEXX Laboratories, Inc. (IDXX) vs Matson Inc (MATX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Matson Inc — how do they compare? IDEXX Laboratories, Inc. trades at $546.1 (market cap $43.58B), while Matson Inc trades at $215.9 (market cap $6.63B). The key difference: IDEXX Laboratories, Inc. is far larger — about 6.6× Matson Inc's market cap, and Matson Inc pays a 0.69% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | MATX | |
|---|---|---|
Market Cap | $43.58B | $6.63B |
Sector | Health | Technology |
52-Week High | $766.68 | $223.55 |
52-Week Low | $526.44 | $88.05 |
Enterprise Value | $44.48B | $7.23B |
Dividend Yield | — | 0.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories trades at $552.46, down 2.64% today, with neutral technical signals but strong fundamental performance. The company maintains robust profitability with 24.63% net margins and has beaten earnings expectations for three consecutive quarters. Recent news highlights AI integration in medical devices and upcoming Q2 2026 results on August 4, 2026. The stock shows consistent revenue growth from $3.4B in 2022 to $4.3B in 2025.
Outlook remains positive given earnings momentum and analyst consensus, though elevated valuation ratios (P/E 41.49) pose risks. Key catalysts include Q2 earnings release and continued AI adoption in veterinary diagnostics. Primary risks involve competitive pressures and market volatility affecting premium valuations.
Matson (MATX) trades at $218.41, down 1.7% today but maintains strong technical momentum with bullish moving averages. The company demonstrates solid fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.85 exceeding expectations. Recent dividend increases and share repurchases highlight management's confidence, while preliminary Q2 2026 results project continued strength in Pacific shipping operations.
The outlook remains positive with analyst consensus favoring buys (64%) and technical indicators supporting upward momentum. Key risks include exposure to Pacific trade volatility and shipping rate fluctuations, but Matson's niche positioning and operational efficiency provide competitive advantages for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →
